|Year : 2016 | Volume
| Issue : 1 | Page : 87-88
An unusual presentation of nonarteritic ischemic optic neuropathy with subretinal fluid treated with intravitreal bevacizumab
Vivek Pravin Dave1, Rajeev R Pappuru2
1 Vitreoretina Services, Netra Mandir Eye Institute, Mumbai, Maharashtra, India
2 Smt. Kanuri Santhamma Center for Vitreo Retinal Diseases, LV Prasad Eye Institute, Hyderabad, Telangana, India
|Date of Submission||01-Nov-2013|
|Date of Acceptance||09-Dec-2015|
|Date of Web Publication||7-Mar-2016|
Vivek Pravin Dave
Consultant Vitreo Retina, Netra Mandir Eye Institute, Madona Colony Road, Borivali W, Mumbai - 400 103, Maharashtra
Source of Support: None, Conflict of Interest: None
A 62-year-old hypertensive male presented with acute nonarteritic ischemic optic neuropathy (NAION) with contiguous macular edema and subretinal fluid in the right eye. Presenting vision was 20/1000. The patient was treated with intravitreal bevacizumab 1.25 mg/0.05 ml. At 1 month follow-up, the macular edema and the optic nerve head edema completely resolved with a good visual improvement up to 20/40. The visual improvement was maintained at the last follow-up 6 months postinjection. Intravitreal bevacizumab may be a good option for acute NAION especially in an unusual presentation with macular edema and subretinal fluid.
Keywords: Avastin, intravitreal bevacizumab, macular edema, nonarteritic ischemic optic neuropathy
|How to cite this article:|
Dave VP, Pappuru RR. An unusual presentation of nonarteritic ischemic optic neuropathy with subretinal fluid treated with intravitreal bevacizumab. Indian J Ophthalmol 2016;64:87-8
|How to cite this URL:|
Dave VP, Pappuru RR. An unusual presentation of nonarteritic ischemic optic neuropathy with subretinal fluid treated with intravitreal bevacizumab. Indian J Ophthalmol [serial online] 2016 [cited 2020 May 26];64:87-8. Available from: http://www.ijo.in/text.asp?2016/64/1/87/178143
Nonarteritic ischemic optic neuropathy (NAION) is one of the most common ischemic optic neuropathies. It causes sudden painless monocular loss of vision typically in patients after their fourth and fifth decades. The etiology is described to be ischemia of the optic nerve due to ciliary circulation insufficiency. In most cases, the natural course of optic disc edema is characterized by spontaneous resolution over 2–3 months culminating optic atrophy and variable levels of final vision loss. Over the years, many therapies have been tried in NAION with varied and limited success including optic nerve sheath decompression, levo L-3,4-dihydroxyphenylalanine (DOPA), intravitreal steroids, and aspirin. Recently, a large prospective study demonstrated the benefit of systemic steroids. As ischemia is the central pathology in NAION, recently intravitreal antivascular endothelial growth factor (VEGF) has shown possible promise. In this case report, we shall discuss a peculiar presentation of NAION with macular edema and subretinal fluid with a favorable response to a single injection of intravitreal bevacizumab.
| Case Report|| |
A 62-year-old controlled hypertensive male presented to us with complaints of blurred vision in the right eye oculus dextrus (OD) since 2 weeks. At a presentation to our clinic, the best-corrected visual acuity (BCVA) in OD was 20/1000 and in the left eye (OS) to be 20/200. Intraocular pressure was 14 mm Hg in both eyes. A relative afferent pupillary defect was noted in OD. Rest of the anterior segment examination was within normal limits in both the eyes. Fundus examination in OD revealed a clear vitreous cavity, pallid disc edema, and macular edema. Localized subretinal fluid on the nasal macula was noted on slit lamp biomicroscopy. OS showed disc pallor with the rest of the retina within normal limits. The patient gave a history of a similar complaint in OS 2 years back. Optical coherence tomography (OCT) and humphrey visual field perimetry were advised. OCT scan through the macula showed neurosensory detachment in OD along with macular edema. A line scan through the optic disc demonstrated severe disc edema [Figure 1]. Perimetry showed an altitudinal visual filed loss characteristic of NAION. There was no history of any other complaints. Blood investigations done included platelet count, erythrocyte sedimentation rate, and C-reactive protein which were all within normal limits.
|Figure 1: (a) Fundus photo showing nonarteritic ischemic optic neuropathy with macular edema (b) perimetry showing classical altitudinal defect (c) macular optical coherence tomography showing subretinal fluid with macular edema (d) optical coherence tomography through nerve head showing disc edema|
Click here to view
The patient was diagnosed as a case of OD acute NAION with subretinal fluid at macula and OS optic atrophy status post-NAION. After discussing the pros and cons of the therapy and with a written informed consent, intravitreal bevacizumab (Avastin, Genentech, San Francisco) 1.25 mg/0.05 ml was injected in OD. At 1 month, the BCVA had improved to 20/40 in OD. OCT at 1 month visit showed completely resolved macular edema and disc edema [Figure 2] 20/40 vision was maintained at the last visit 3 months postinjection.
|Figure 2: (a) Fundus photo showing resolved disc edema and pallor (b) resolved subretinal fluid (c) resolved disc edema|
Click here to view
| Discussion|| |
Pathogenesis of NAION can be explained by “compartment syndrome” and reperfusion injury as shown by Chen et al. It can be hypothesized that there is local VEGF release which causes early vasogenic edema of the optic nerve head. Anti-VEGF can reduce this early vasogenic edema and decrease the severity of the compartment syndrome thus leading to a better final visual outcome. Bajin et al. in their study of four eyes showed visual improvement after injecting intravitreal ranibizumab for NAION. Pece et al. and Arnold and Hepler in their study, on the other hand, showed no visual improvement in vision after intravitreal ranibizumab., Rootman et al. in a prospective trial found no difference between bevacizumab and natural history for change in visual field, visual acuity, or optic nerve OCT thickness. Saatci et al. found a beneficial effect of intravitreal ranibizumab in their case series of 17 eyes.
Macular edema is an unusual presentation in NAION not described as a part of the natural history of NAION. Neither is it described in the fluorescein angiography features nor in cases with giant cell arteritis.,, It most likely represents spillover edema from the optic nerve head. Very few case reports suggest the presence of macular star associated with cases of NAION., It has been hypothesized that there may be a better visual outcome in these subset of patients postresolution of macular edema and that some sort of therapy toward resolution of macular edema may be warranted.
To the best of our knowledge, this is the first case of NAION with macular edema and subretinal fluid treated with intravitreal bevacizumab with good visual outcome. Further, large studies are warranted to elucidate a clear role of intravitreal anti-VEGF therapy in NAION though our case report shows a possible role in concurrent macular edema.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Hayreh SS. Anterior ischaemic optic neuropathy. I. Terminology and pathogenesis. Br J Ophthalmol 1974;58:955-63.
Repka MX, Savino PJ, Schatz NJ, Sergott RC. Clinical profile and long-term implications of anterior ischemic optic neuropathy. Am J Ophthalmol 1983;96:478-83.
Hayreh SS, Zimmerman MB. Non-arteritic anterior ischemic optic neuropathy: Role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol 2008;246:1029-46.
Chen CS, Johnson MA, Flower RA, Slater BJ, Miller NR, Bernstein SL. A primate model of nonarteritic anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci 2008;49:2985-92.
Bajin MS, Selver OB, Taskin O, Yaman A, Saatci AO. Single intravitreal ranibizumab injection in eyes with acute non-arteritic anterior ischaemic optic neuropathy. Clin Exp Optom 2011;94:367-70.
Pece A, Querques G, Quinto A, Isola V. Intravitreal ranibizumab injection for nonarteritic ischemic optic neuropathy. J Ocul Pharmacol Ther 2010;26:523-7.
Arnold AC, Hepler RS. Fluorescein angiography in acute nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1994;117:222-30.
Rootman DB, Gill HS, Margolin EA. Intravitreal bevacizumab for the treatment of nonarteritic anterior ischemic optic neuropathy: A prospective trial. Eye (Lond) 2013;27:538-44.
Saatci AO, Taskin O, Selver OB, Yaman A, Bajin MS. Efficacy of intravitreal ranibizumab injection in acute nonarteritic ischemic optic neuropathy: A long-term follow up. Open Ophthalmol J 2013;7:58-62.
Siatkowski RM, Gass JD, Glaser JS, Smith JL, Schatz NJ, Schiffman J. Fluorescein angiography in the diagnosis of giant cell arteritis. Am J Ophthalmol 1993;115:57-63.
Wang AG, Lui JH, Lin CL, Yen MY. Macular star in optic neuropathy. Am J Ophthalmol 1995;27:107-12.
Tomsak RL, Zakov ZN. Nonarteritic anterior ischemic optic neuropathy with macular edema: Visual improvement and fluorescein angiographic characteristics. J Neuroophthalmol 1998;18:166-8.
[Figure 1], [Figure 2]